

## Cerecor Inc.

(CERC-NASDAQ)

**CERC: Data from CDG-FIRST Trial Upcoming...**

Based on our probability adjusted DCF model that takes into account potential future revenues from the company's rare and orphan disease pipeline along with the sale of PRVs, and using a 13.5% discount rate CERC is valued at \$7.00/share.

Current Price (03/19/20) **\$2.02**  
Valuation **\$7.00**

## OUTLOOK

Cerecor Inc. (CERC) underwent a transformative 2019 and has emerged in 2020 ready to capitalize on its new strategy as an orphan and rare disease-focused biotech company. Following the divestiture of the company's pediatric portfolio and elimination of its debt overhang, Cerecor merged with Aevi Genomic Medicine, which greatly expanded the development pipeline. Looking ahead to the next six to 12 months, we anticipate initial data from the CDG-FIRST trial for the CERC-800 series in the first half of 2020, initial data from CERC-002 (anti-LIGHT mAb) in the second half of 2020, initial data for CERC-007 (anti-IL-18 mAb) in late 2020 or early 2021, and initial data for CERC-006 (dual mTOR inhibitor) in the first half of 2021.

## SUMMARY DATA

52-Week High **\$6.22**  
52-Week Low **\$1.70**  
One-Year Return (%) **-65.47**  
Beta **2.36**  
Average Daily Volume (sh) **108,545**

Shares Outstanding (mil) **58**  
Market Capitalization (\$mil) **\$116**  
Short Interest Ratio (days) **N/A**  
Institutional Ownership (%) **52**  
Insider Ownership (%) **64**

Annual Cash Dividend **\$0.00**  
Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates  
Sales (%) **N/A**  
Earnings Per Share (%) **N/A**  
Dividend (%) **N/A**

P/E using TTM EPS **N/A**  
P/E using 2018 Estimate **-4.4**  
P/E using 2019 Estimate **-6.6**

Risk Level **High**  
Type of Stock **Small-Growth**  
Industry **Med-Biomed/Gene**

## ZACKS ESTIMATES

	Revenue (in millions of \$)				
	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2019	5.4 A	4.4 A	5.5 A	-8.6 A	6.8 A
2020	2.0 E	2.0 E	2.0 E	2.0 E	8.0 E
2021					8.0 E
2022					8.0 E

## Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2019	-\$0.13 A	-\$0.11 A	-\$0.07 A	\$0.03 A	-\$0.38 A
2020	-\$0.13 E	-\$0.11 E	-\$0.07 E	-\$0.12 E	-\$0.50 E
2021					-\$0.51 E
2022					-\$0.55 E

## WHAT'S NEW

### Financial Update

On March 11, 2020, Cerecor, Inc. (CERC) [announced](#) financial results for the fourth quarter and full year 2019. The company reported net product revenue of \$6.7 million for 2019 compared to \$6.6 million for 2018. These revenues were derived from the sale of Millipred<sup>®</sup>, which is the company's only remaining commercial product following the sale of the Pediatric Portfolio to Aytu Bioscience, Inc. (AYTU) in October 2019. R&D expenses in 2019 were \$11.8 million compared to \$5.8 million in 2018. The increase was the result of increased expenses for the development of the CERC-800 series and increased CMC expenses. G&A expenses for 2019 were \$10.1 million compared to \$10.5 million for 2018. The slight decrease was primarily due to decreased legal, consulting, and professional fees.

Cerecor exited 2019 with approximately \$3.6 million in cash and cash equivalents. Subsequent to the end of the quarter the company raised approximately \$5 million in net proceeds from a registered direct offering in which approximately 1.3 million shares were sold for \$3.98 per share. The company has a number of near-term opportunities to raise the necessary capital to get through the first NDA filing for the CERC-800 series:

- 1) An agreement is in place with the company's majority shareholder, Armistice Capital, in which Armistice can provide up to \$15 million in financing.
- 2) The company is actively looking to sell Millipred. We believe Millipred generates approximately \$8 million in yearly net revenues and approximately \$7 million in free cash flow. Using a 2-3x free cash flow multiple, we estimate that it could be sold for \$15-20 million.
- 3) Cerecor owns approximately 9.8 million shares of Aytu Series G Preferred Stock, with the restriction period on those shares ending in June 2020. Aytu shares have appreciated >200% in the past month due to the fact the company sells a coronavirus test kit.

The company will need to finance operations until the approval of the first CERC-800 series product, which will come with a priority review voucher (PRV) that can likely be monetized for approximately \$100 million. We anticipate this will happen in 2022.

As of March 9, 2020, Cerecor had approximately 57.6 million shares outstanding and when factoring in options and warrants a fully diluted share count of approximately 66.4 million.

### Business Update

#### *Acquisition of Aevi Genomic Medicine Strengthens Rare and Orphan Disease Pipeline*

On February 3, 2020, Cerecor [announced](#) the completion of the merger with Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately \$16.1 million plus contingent value rights (CVRs) for up to an additional \$6.5 million based on subsequent clinical or regulatory milestones. The company is continuing to explore strategic alternatives for CERC-301 and Millipred, which was not included in the sale of the company's Pediatric Portfolio.

The rationale behind the acquisition of Aevi centered on Cerecor's desire to expand its rare disease pipeline, which now includes three clinical-stage programs from Aevi in addition to the 800-series programs. In addition, the CEO and CMO from Aevi, Mike Cola and Dr. Garry Neil, joined Cerecor as the company did not have anyone in either position prior to the acquisition.

The three programs that Cerecor acquired from Aevi are:

**AEVI-007:** This is an anti-interleukin (IL)-18 fully human monoclonal antibody that will be developed for the treatment of Adult Onset Stills Disease (AOSD) and multiple myeloma (MM). We anticipate proof-of-concept clinical trials initiating in 2020.

- AOSD is an inflammatory disease in which patients suffer from high fevers, sore throat, joint pain, swollen lymph nodes, and weight loss. The cause is unknown and no risk factors have been identified. Approximately 1 in 100,000 people develop AOSD each year and it becomes a chronic condition in

approximately 1/3<sup>rd</sup> of those affected (Medlineplus). We estimate there are approximately 4,000 patients in the U.S. with AOSD.

- MM is a cancer of monoclonal plasma cells that derive from post-germinal-center B cells. The disease is characterized by an infiltration of these cells into the bone marrow causing anemia, lytic bone disease, hypercalcemia, and kidney damage from the accumulation of monoclonal immunoglobulins (Kumar *et al.*, 2017). The disease is most common in the elderly, with a median age of onset of 69 years (NCI SEER). Elevated IL-18 serum levels are associated with poor overall survival in MM patients (Alexandrakis *et al.*, 2004) and IL-18 drives the generation of myeloid-derived suppressor cells (MDSCs) that accelerate disease progression (Nakamura *et al.*, 2018).

**AEVI-006:** This is a small molecule inhibitor of the mTORC1/2 complexes that is being developed for the treatment of complex lymphatic malformation (LM). LMs are rare, non-malignant masses composed of fluid-filled channels or spaces caused by the improper formation of the lymphatic system. The abnormal lymphatic vessels cause the slow transfer of lymphatic fluid back into the venous system, thus excessive fluid accumulates and dilates the lymphatic channels. LMs form prior to birth and are typically identified within the first two years of life. They most commonly affect the head and neck area but can occur anywhere in the body. They affect approximately 50,000 individuals in the U.S.

The cellular receptor TIE2 plays a key role in vascular maturation through the PI3K/AKT/mTOR signaling pathway, and up to 60% of venous malformations are caused by mutations in TIE2 (Hammer *et al.*, 2018) while another 20% are due to mutations in PIK3CA, which encodes the catalytic subunit of PI3K (Limaye *et al.*, 2015).

Sunitinib is an allosteric inhibitor of mTOR, the catalytic subunit of two distinct complexes: mTORC1 and mTORC2. It inhibits mTORC1 (Tsang *et al.*, 2007) but only inhibits mTORC2 in certain cell types after prolonged exposure (Sarbasov *et al.*, 2006).

A systematic review identified twenty studies that included 71 patients with vascular malformations (45 patients with LM) treated with sunitinib (Wiegand *et al.*, 2018). Despite dosing and duration of treatment differences, 60 patients experienced a partial remission of disease. Thus, we believe these data provide compelling justification for testing an mTORC1/2 inhibitor for the treatment of LM. Cerecor intends to start a Phase 1b proof-of-concept trial by the end of 2020.

**AEVI-002:** This is a fully human monoclonal antibody targeting LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes [part of the Tumor Necrosis Super Family 14]). The compound is currently in a Phase 1 clinical trial in adult patients with Crohn's disease (CD), and the company is planning to initiate a clinical trial for pediatric Crohn's disease.

Crohn's disease is chronic type of inflammatory bowel disease of the digestive tract in which patients experience diarrhea, cramping and pain in the abdomen, and weight loss (NIDDK). The cause of CD is unknown but is thought to be an interplay between various genetic and environmental factors. Current treatment options work to decrease the inflammation and to prevent its recurrence, however there is no cure for the disease. Corticosteroids, immunomodulators, and biologic therapies that targets tumor necrosis factor-alpha, IL-12, or IL-23 are examples of currently available treatments.

Previous preclinical research showed that LIGHT expression caused similar pathological features and cytokine characterization that is observed in CD (Wang *et al.*, 2005), which forms the basis for potentially treating Crohn's patients with an anti-LIGHT antibody. The company has developed a validated assay to quantify the levels of LIGHT in patients, thus making patient selection and monitoring more efficient. Aevi previously initiated a clinical trial of AEVI-002 in adult Crohn's disease patients (NCT03169894) and we anticipate initial data from this study in the second half of 2020 before Cerecor can initiate a trial in pediatric Crohn's patients in 2021.

#### *CERC-800 Series Update*

Cerecor is developing CERC-801 (D-galactose), CERC-802 (D-mannose), and CERC-803 (L-fucose) for the treatment of the congenital disorder of glycosylation (CDG) diseases phosphoglucomutase 1 (PGM1) deficiency, mannose-phosphate isomerase (MPI) deficiency, and leukocyte adhesion deficiency type II (LADII) or SLC35C1-CDG, respectively.

In July 2019, the company announced the first patient was enrolled in the CDG FIRST (Congenital Disorders of Glycosylation Formative Retrospective Study) trial. The purpose of the CDG FIRST trial is to collect natural history

data from patients diagnosed with CDGs along with any treatment-related data whether or not they had been treated with D-galactose, D-mannose, or L-fucose. Earlier in 2019, the FDA issued draft guidance on the use of natural history studies for drug development in rare diseases. Since the natural history, or the course a disease would take with no intervention, is typically limited for rare diseases, these types of studies are important to help understand the most useful types of outcomes to monitor.

We believe the company is hoping to collect data from approximately 10 patients each for CERC-801 and CERC-802 while for CERC-803 only a few patients will likely be needed given that it is incredibly rare. We anticipate initial data from this study in the first half of 2020. We don't believe any prospective study required by the FDA will be onerous and will likely only require up to 10 patients each for CERC-801 and CERC-802 and potentially only a couple of patients for CERC-803. Precedent for a very small prospective trial is provided by Xuriden® (uridine triacetate), which was approved by the FDA in 2015 following an open-label study in four patients with hereditary orotic aciduria. Three of the four patients had previously been treated with uridine before being switched to Xuriden®.

The first NDA filing should occur in 2021 with an expected approval in 2022. Which compound the first NDA is filed for will be determined by the rate at which the prospective studies occur. However, since all of the CERC-800 compounds qualify for a priority review voucher (discussed below), it doesn't make a difference which compound is approved first.

### Potential for Priority Review Voucher

Given that the number of patients for each of the CERC-800 products is very small, the most important aspect for those products is likely the fact that they are eligible for a priority review voucher (PRV) upon approval. A PRV allows the holder of the voucher to receive an expedited six-month review from the FDA for an NDA or biologics license application (BLA) instead of the usual ten-month review. The Food and Drug Administration Safety and Innovation Act (FDASIA) created the rare pediatric voucher in 2012 to specifically target the need for additional therapies for rare pediatric subsets of diseases (affect fewer than 200,000 individuals in the U.S.). Priority review vouchers are also awarded for the development of treatments for certain tropical diseases and medical countermeasures.

Priority review vouchers are fully transferrable, and a number of companies that have been issued the vouchers in the past have sold them, including one that was sold to AbbVie (ABBV) in Aug. 2015 for \$350 million. The four most recent purchases are by Biohaven Pharmaceutical Holding Company for \$105 million in Mar. 2019, AstraZeneca (AZN) for \$95 million in Aug. 2019, an undisclosed buy for \$95 million in Dec. 2019, and Vifor for \$111 million in Feb. 2020. While prices for PRVs have come down since AbbVie purchased one for \$350 million in 2015, the price for them appears to have settled to approximately \$100 million. The following table shows how many PRVs have been issued along with the current status of the voucher, if known.

Priority Review Vouchers			
Voucher Award Date	Voucher Type	Voucher Awardee	Voucher Status
2009	Tropical Disease	Novartis	Used for BLA for canakinumab
2012	Tropical Disease	Janssen	Used to accelerate approval of Tremfya (guselkumab) for plaque psoriasis
2014	Rare Pediatric Disease	BioMarin	Sold to Sanofi for \$67.5M in Jul 2014; used for approval of Praluent
2014	Tropical Disease	Knight Therapeutics	Sold to Gilead for \$125M in Nov 2014; used for approval of Odsafey
2015	Rare Pediatric Disease	United Therapeutics	Sold to AbbVie for \$350M in Aug 2015
2015	Rare Pediatric Disease	Asklepion Pharmaceuticals	Transferred to Retrophin and sold to Sanofi for \$245M in May 2015
2015	Rare Pediatric Disease	Wellstat Therapeutics	Transferred to AstraZeneca
2015	Rare Pediatric Disease	Alexion Pharmaceuticals	Used for approval of ALXN1210
2015	Rare Pediatric Disease	Alexion Pharmaceuticals	Not used
2016	Tropical Disease	PaxVax Bermuda	Not used (possibly sold to Gilead for ~\$200M in 2016)
2016	Rare Pediatric Disease	Sarepta Therapeutics	Sold to Gilead for \$125M in Feb 2017; used for approval of HIV treatment
2016	Rare Pediatric Disease	Ionis Pharmaceuticals	Not used
2017	Rare Pediatric Disease	Marathon Pharmaceuticals	Not used
2017	Rare Pediatric Disease	BioMarin	Sold for \$125 million in Nov 2017
2017	Tropical Disease	Chemo Research, S.L.	Not used
2017	Rare Pediatric Disease	Novartis	Used for brotuzumab for wetAMD
2017	Rare Pediatric Disease	Ultragenyx Pharmaceutical	Sold to Novartis for \$130 million in Dec. 2017; used for approval of siponimod
2017	Rare Pediatric Disease	Spark Therapeutics	Sold to Jazz Pharmaceuticals for \$110 million in Apr 2018
2018	Rare Pediatric Disease	Ultragenyx Pharmaceutical	Sold to Gilead for \$60.6 million in Aug. 2018
2018	Rare Pediatric Disease	Medicines Development	Sold to Novo Nordisk for undisclosed amt
2018	Rare Pediatric Disease	GW Pharma	Sold to Biohaven for \$105 million on Mar. 16, 2019
2018	Material Threat Medical Countermeasure	SIGA Technologies	Sold to Eli Lilly for \$80 million on Nov. 1, 2018
2018	Tropical Disease	GlaxoSmithKline	Used by VIV Healthcare for NDA for HIV-1 infection
2018	Rare Pediatric Disease	Leadiant Bioscience Inc	Not used
2018	Rare Pediatric Disease	Sobi and Novimmune	Sold to AZN for \$95 million in Aug 2019
2019	Tropical Disease	Novartis	Used for BLA for ofatumumab
2019	Rare Pediatric Disease	Vertex	Not used
2019	Rare Pediatric Disease	Alexion Pharmaceuticals	Not used
2019	Tropical Disease	Sanofi	Not used
2019	Rare Pediatric Disease	Novartis	Used for BLA for secukinumab
2019	Tropical Disease	TB Alliance	Not used
2019	Material Threat Medical Countermeasure	Bavarian Nordic	Sold to undisclosed buyer for \$95 million in Dec. 2019
2019	Rare Pediatric Disease	Vertex	Not used
2019	Rare Pediatric Disease	Sarepta Therapeutics	Sold to Vifor in Feb. 2020 for \$111 million
2019	Tropical Disease	Merck	Not used

Source: rppa.org / Zacks SCR

## **Conclusion and Valuation**

Following the acquisition of Aevi and the sale of the Pediatric Portfolio, Cerecor is now fully focused on a diverse pipeline of assets targeting rare and orphan diseases. The company now has no debt on its balance sheet and a number of options available for financing to an expected PRV in 2022, with three other PRV's possible over the following few years.

For the CERC-800 series, the majority of the valuation comes from the potential PRVs to be issued upon approval of each of the compounds. However, the company will be commercializing the products as well and we estimate that the CERC-800 series compounds could generate peak sales of \$100 million. We model for three PRVs to be issued in 2022 and 2023 and currently use an 80% probability of approval. We also model for each PRV to be sold within a year of being issued. Using a 13.5% discount rate leads to a net present value for the CERC-800 series of \$215 million.

For the Aevi assets, we currently estimate that Cerecor will commercialize each of the assets in the U.S., although if AEVI-007 is advanced in MM, we believe that will be done through a partnership. For sales outside the U.S., we estimate that each compound will be partnered and the company will receive a 15% royalty on net sales.

For AEVI-007 in AOSD, we estimate there are approximately 4,000 individuals in the U.S. and approximately 6,000 in the rest of the world with the condition. Based on the literature, approximately 30% of patients are refractory to front-line methotrexate therapy and thus would be the target population for treatment with AEVI-007. Based on approval in 2025, a \$250,000 yearly cost, peak sales of \$250 million in the U.S. and \$150 million in the rest of the world, and using a 13.5% discount rate and a 20% probability of approval leads to a net present value for AEVI-007 in AOSD of approximately \$16 million.

For AEVI-007 in MM, we estimate there are approximately 30,000 and 39,000 individuals with the disease in the U.S. and E.U., respectively. We estimate for approval in 2027, peak sales of \$700 million in the U.S. and \$400 million in the E.U., and using a 13.5% discount rate and a 20% probability of approval leads to a net present value for AEVI-007 in MM of approximately \$35 million.

For AEVI-006 in LM, we estimate there are approximately 50,000 and 60,000 individuals with the condition in the U.S. and E.U., respectively. We estimate for approval in 2024 in the U.S. and 2025 in the E.U., peak sales of \$600 million in the U.S. and \$700 million in the E.U., and using a 13.5% discount rate and a 20% probability of approval leads to a net present value for AEVI-006 in LM of approximately \$68 million.

For AEVI-002 for pediatric Crohn's, we estimate there are approximately 50,000 and 75,000 individuals with the condition in the U.S. and E.U., respectively. We estimate for approval in 2026 in the U.S. and 2027 in the E.U., peak sales of \$400 million in both the U.S. and E.U., and using a 13.5% discount rate and a 20% probability of approval leads to a net present value for AEVI-002 in pediatric Crohn's of approximately \$26 million.


Combining the net present value for the CERC-800 series, the Aevi assets, a \$15 million valuation for Millipred®, a \$20 million valuation for the legacy neurology assets, and the company's current cash total and dividing by the current share count of approximately 57.6 million shares leads to a valuation for Cerecor of \$7 per share.

## PROJECTED FINANCIALS

Cerecor, Inc.	2019 A	Q1 E	Q2 E	Q3 E	Q4 E	2020 E	2021 E	2021 E
Commercial Group	\$6.7	\$2.0	\$2.0	\$2.0	\$2.0	\$8.0	\$8.0	\$8.0
Rare Disease Portfolio	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
PRV Revenue	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Grant Revenue	\$0.1	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
<b>Total Revenues</b>	<b>\$6.8</b>	<b>\$2.0</b>	<b>\$2.0</b>	<b>\$2.0</b>	<b>\$2.0</b>	<b>\$8.0</b>	<b>\$8.0</b>	<b>\$8.0</b>
Cost of Sales	(\$0.6)	\$0.3	\$0.3	\$0.3	\$0.3	\$1.0	\$1.0	\$1.0
<i>Product Gross Margin</i>	108%	88%	88%	88%	88%	88%	88%	88%
Research & Development	\$11.8	\$4.5	\$4.8	\$5.0	\$5.3	\$19.6	\$24.0	\$26.0
Acquired in-process R&D	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
General & Administrative	\$10.1	\$2.8	\$2.9	\$3.0	\$3.1	\$11.8	\$12.0	\$12.5
Sales and Marketing	\$1.5	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Amortization Expense	\$1.3	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Impairment of Intangible Assets	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Change in fair value of contingent consideration	(\$1.3)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
<b>Operating Income</b>	<b>(\$16.1)</b>	<b>(\$5.6)</b>	<b>(\$6.0)</b>	<b>(\$6.3)</b>	<b>(\$6.7)</b>	<b>(\$24.4)</b>	<b>(\$29.0)</b>	<b>(\$31.5)</b>
<i>Operating Margin</i>	-239%	-	-	-	-	-305%	-363%	-394%
Other (expense) income	\$0.1	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	(\$1.2)	(\$1.2)
<b>Pre-Tax Income</b>	<b>(\$16.0)</b>	<b>(\$5.6)</b>	<b>(\$6.0)</b>	<b>(\$6.3)</b>	<b>(\$6.7)</b>	<b>(\$24.4)</b>	<b>(\$30.2)</b>	<b>(\$32.7)</b>
Income Taxes Paid	\$0.3	\$0.1	\$0.1	\$0.1	\$0.1	\$0.4	\$0.1	\$0.1
<b>Net Income</b>	<b>(\$16.3)</b>	<b>(\$5.7)</b>	<b>(\$6.1)</b>	<b>(\$6.4)</b>	<b>(\$6.8)</b>	<b>(\$24.8)</b>	<b>(\$30.3)</b>	<b>(\$32.8)</b>
<i>Net Margin</i>		-	-	-	-			
<b>Reported EPS</b>	<b>(\$0.38)</b>	<b>(\$0.13)</b>	<b>(\$0.11)</b>	<b>(\$0.07)</b>	<b>(\$0.12)</b>	<b>(\$0.43)</b>	<b>(\$0.51)</b>	<b>(\$0.55)</b>
<i>YOY Growth</i>		-	-	-	-			
Basic Shares Outstanding	42.9	57.6	58.0	58.0	58.0	57.9	60.0	60.0

Source: Zacks Investment Research, Inc. David Bautz, PhD

## HISTORICAL STOCK PRICE



Source: Zacks Small Cap Research

## DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

### ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

### INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article. Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

### POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

### ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

### CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.